

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Orphan Disease Treatment Institute Office Opens inside Daiichi Sankyo Shinagawa R&D Center

Tokyo, Japan (April 1, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today the opening of the office of the Orphan Disease Treatment Institute Co., Ltd. (hereafter, Orphan Disease Treatment Institute) inside the Daiichi Sankyo Shinagawa R&D center. The establishment of the Orphan Disease Treatment Institute was announced on February 14, 2013, in a press release entitled, “Daiichi Sankyo Announces Development of Nucleic Acid Treatment for Duchenne Muscular Dystrophy Utilizing Proprietary Technology.”

With today’s office opening, the new company can now begin to fully undertake development of a treatment for Duchenne muscular dystrophy.

The Orphan Disease Treatment Institute was financed through joint investment from Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital Co., Ltd and Daiichi Sankyo.

Profile of Orphan Disease Treatment Institute Co., Ltd.

1. Company name: Orphan Disease Treatment Institute Co., Ltd.
2. Date of establishment: March 1, 2013
3. Location: Hiromachi 1-2-58, Shinagawa-ku, Tokyo
(inside the Daiichi Sankyo Shinagawa R&D center)
4. Management structure: Makoto Hanada, President
Hidemi Masumura, Director
Shigeyuki Tsuchida, Director
Nobutake Morii, Director
Yoshitaka Fukui, Auditor
5. Capital/capital reserves: 450 million yen
6. Business: Development of a treatment for Duchenne muscular dystrophy
7. Employees: 2

###